Access to the new Alzheimer's drugs is limited by strict eligibility criteria, long wait times, and a lack of infusion centers.

Much has changed since the 2013 document came out, with new information on pacing devices, techniques, and more.

Dr. Joao de Quevedo with UTHealth Houston shares what researchers found during a clinical trial for Spravato, the first FDA-approved nasal spray to treat depression.

Because of this, the Food and Drug Administration (FDA) announced on January 17 that the agency is implementing a new strategy to lower the risk of certain viruses ending up in your berries. They're ...